| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
ERK MAPK signaling pathway. ACA-28 is an ERK MAPK modulator that induces apoptosis in melanoma cells through excessive ERK activation. It can also activate nuclear factor erythroid 2-related factor 2 (Nrf2) signaling via inducing reactive oxygen species (ROS) production. ACA-28 selectively downregulates DUSP6 and inhibits cancer cell growth.
|
|---|---|
| ln Vitro |
ACA-28 inhibits cell growth of melanoma cells (SK-MEL-28) and normal melanocytes (NHEM) with IC50 values of 5.3 microM and 10.1 microM, respectively. In A4-15 cells, ACA-28 (0-10 microM) selectively downregulates DUSP6 and inhibits cell proliferation as measured by WST-8 assay. The compound shows greater potency against cancer cells compared to normal cells, indicating selectivity.
|
| ln Vivo |
No detailed in vivo activity data for ACA-28 are provided in the reference sources. The compound is a research tool for studying ERK MAPK signaling and its role in cancer cell apoptosis. In vivo studies would likely involve subcutaneous melanoma xenograft mouse models with daily oral administration for several weeks.
|
| Enzyme Assay |
Not explicitly detailed in reference sources. A standard ERK activation assay involves treating cells with ACA-28 (0-10 microM) for varying time periods, lysing cells, and measuring phospho-ERK and total ERK levels by Western blot using specific antibodies. Kinase activity can also be measured using recombinant ERK and a substrate peptide in an in vitro kinase assay.
|
| Cell Assay |
Not explicitly detailed in reference sources. A standard cell viability assay for ACA-28 involves seeding SK-MEL-28 melanoma cells in 96-well plates, treating with ACA-28 at 0-10 microM for 72 hours, and measuring cell viability using WST-8 reagent followed by absorbance measurement at 450 nm. IC50 values are calculated from dose-response curves.
|
| Animal Protocol |
No in vivo animal experimental protocols for ACA-28 are provided in the reference sources. Typical in vivo studies for ERK modulators involve subcutaneous injection of cancer cells into immunocompromised mice, allowing tumor establishment, and then oral or intraperitoneal administration of ACA-28 daily for 2-4 weeks with monitoring of tumor growth and body weight.
|
| ADME/Pharmacokinetics |
Not explicitly detailed in reference sources. ACA-28 has a molecular weight of 316.31 and formula C17H16O6. It is soluble in DMSO (80 mg/mL, 252.92 mM). For in vivo formulation, a mixture of 10% DMSO + 40% PEG300 + 5% Tween80 + 45% saline is used (≥2.5 mg/mL). The compound should be stored as powder at -20degC for long-term stability.
|
| Toxicity/Toxicokinetics |
No detailed toxicity data for ACA-28 are provided in the reference sources. As with all research compounds, standard safety precautions should be followed. Toxicity assessments would typically involve monitoring body weight, clinical signs, and tissue histopathology in animal models. The compound is for research use only and not intended for human therapeutic use.
|
| References | |
| Additional Infomation |
ACA-28 is a research compound not yet approved for clinical use. Its unique mechanism of inducing cancer cell death via ERK hyperactivation represents a potential alternative to conventional ERK inhibitors for melanoma and other cancers. The compound is available for research purposes only. Further studies are needed to evaluate its in vivo efficacy and safety profile.
|
| Molecular Formula |
C17H16O6
|
|---|---|
| Molecular Weight |
316.305345535278
|
| Exact Mass |
316.094
|
| CAS # |
948044-25-5
|
| PubChem CID |
44574021
|
| Appearance |
White to off-white solid powder
|
| LogP |
3.9
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
23
|
| Complexity |
383
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
COC(=O)OC1=CC=C(C=C1)C(C2=CC=CC=C2)OC(=O)OC
|
| InChi Key |
UZLVJKSHIATGCE-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C17H16O6/c1-20-16(18)22-14-10-8-13(9-11-14)15(23-17(19)21-2)12-6-4-3-5-7-12/h3-11,15H,1-2H3
|
| Chemical Name |
[4-[methoxycarbonyloxy(phenyl)methyl]phenyl] methyl carbonate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~316.15 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.90 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (7.90 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (7.90 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.1615 mL | 15.8073 mL | 31.6146 mL | |
| 5 mM | 0.6323 mL | 3.1615 mL | 6.3229 mL | |
| 10 mM | 0.3161 mL | 1.5807 mL | 3.1615 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
